182 related articles for article (PubMed ID: 23211022)
41. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug N; Cramer P; Robrecht S; Bahlo J; Westermann A; Fink AM; Schrader A; Mayer P; Oberbeck S; Seiler T; Zenz T; Dürig J; Kreuzer KA; Stilgenbauer S; Eichhorst B; Hallek M; Herling M; Hopfinger G
Leuk Lymphoma; 2019 Mar; 60(3):649-657. PubMed ID: 30234404
[TBL] [Abstract][Full Text] [Related]
42. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
43. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
[TBL] [Abstract][Full Text] [Related]
45. T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities.
Wei Q; Papavassiliou P; Rehder C; Sebastian S; Wang E
Pathol Res Pract; 2014 Dec; 210(12):1100-5. PubMed ID: 25238936
[TBL] [Abstract][Full Text] [Related]
46. Clinical analysis of prolymphoblastic leukemia: the rare hematological malignancy in the elderly.
Yan Z; Zeng M; Chen X; Yin Y; Liu Y
Am J Transl Res; 2023; 15(9):5653-5663. PubMed ID: 37854229
[TBL] [Abstract][Full Text] [Related]
47. Management of chronic lymphocytic leukaemia.
Kalil N; Cheson BD
Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
[TBL] [Abstract][Full Text] [Related]
48. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
Shvidel L; Shtalrid M; Bassous L; Klepfish A; Vorst E; Berrebi A
Leuk Lymphoma; 1999 Mar; 33(1-2):169-79. PubMed ID: 10194135
[TBL] [Abstract][Full Text] [Related]
49. A T-cell prolymphocytic leukemia case with central nervous system involvement.
Malkan UY; Gunes G; Yayar O; Demiroglu H; Yesilirmak A; Uner A
Int J Clin Exp Med; 2015; 8(8):14207-9. PubMed ID: 26550397
[TBL] [Abstract][Full Text] [Related]
50. T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis.
Yoshioka Y; Nagao M; Saitoh T; Yoshioka S; Tsunemine H; Itoh K; Kodaka T; Takahashi T
J Clin Exp Hematop; 2015; 55(1):17-21. PubMed ID: 26106002
[TBL] [Abstract][Full Text] [Related]
51. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
52. [T-cell prolymphocytic leukemia complicated by diffuse large B-cell lymphoma of the stomach].
Miyata A; Yoshino T; Kojima K; Fujii S; Kikuchi T
Rinsho Ketsueki; 2001 Jan; 42(1):47-50. PubMed ID: 11235134
[TBL] [Abstract][Full Text] [Related]
53. De-novo CD5 + B- prolymphocytic leukemia (PLL) presenting at younger age with favourable outcome.
Kar R; Kumar R; Tyagi S
Turk J Haematol; 2008 Sep; 25(3):149-51. PubMed ID: 27264708
[TBL] [Abstract][Full Text] [Related]
54. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia.
Gritti C; Dastot H; Soulier J; Janin A; Daniel MT; Madani A; Grimber G; Briand P; Sigaux F; Stern MH
Blood; 1998 Jul; 92(2):368-73. PubMed ID: 9657733
[TBL] [Abstract][Full Text] [Related]
55. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
56. T-cell Prolymphocytic Leukemia.
Matutes E
Cancer Control; 1998 Jan; 5(1):19-24. PubMed ID: 10761013
[TBL] [Abstract][Full Text] [Related]
57. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
58. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
Madaris L
J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
[TBL] [Abstract][Full Text] [Related]
59. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
